Abstract:BACKGROUND: The past decade has witnessed an ever-increasing momentum of transcatheter aortic valve replacement (TAVR) and a subsequent paradigm shift in the contemporary management of severe aortic stenosis (AS). We conducted a multi-centric TAVR registry based on Chinese patients (the China Aortic valve tRanscatheter Replacement registrY [CARRY]) to delineate the clinical characteristics and outcomes of Chinese patients who underwent TAVR and compare the results between different valve types in different Chinese regions.METHODS: CARRY is an all-comer registry of aortic valve disease patients undergoing TAVR across China and was designed as an observational study that retrospectively included all TAVR patients at each participating site. Seven hospitals in China participated in the CARRY, and 1204 patients from April 2012 to November 2020 were included. Categorical variables were compared using the chi-squared test, and continuous variables were analyzed using a t test or analysis of variance (ANOVA) test. The Kaplan-Meier curve was used to estimate the risk of adverse events during follow-up.RESULTS: The mean age of the patients was 73.8 ± 6.5 years and 57.2% were male. The median Society of Thoracic Surgeon-Predicted Risk of Mortality score was 6.0 (3.7-8.9). Regarding the aortic valve, the proportion of bicuspid aortic valve (BAV) was 48.5%. During the hospital stay, the stroke rate was 0.7%, and the incidence of high-degree atrioventricular block indicating permanent pacemaker implantation was 11.0%. The in-hospital all-cause mortality rate was 2.2%. After 1 year, the overall mortality rate was 4.5%. Compared to patients with tricuspid aortic valve (TAV), those with BAV had similar in-hospital complication rates, but a lower incidence of in-hospital mortality (1.4% vs. 3.3%) and 1 year mortality (2.3% vs. 5.8%).CONCLUSIONS: TAVR candidates in China were younger, higher proportion of BAV, and had lower rates of post-procedural complications and mortality than other international all-comer registries. Given the use of early generation valves in the majority of the population, patients with BAV had similar rates of complications, but lower mortality than those with TAV. These findings further propel the extension of TAVR in low-risk patients.TRIAL REGISTRATION: https://www.chictr.org.cn/ (No. ChiCTR2000038526).

The current situation of transcatheter aortic valve replacement in China 2017

First Two Cases of Transcatheter Aortic Valve Replacement with Lotus Valve System in China

Severe Symptomatic Bicuspid and Tricuspid Aortic Stenosis in China: Characteristics and Outcomes of Transcatheter Aortic Valve Replacement with the Venus-A Valve (vol 2, pg 60, 2018)

Clinical practice and prognosis of emergent transcatheter aortic valve replacement

Twelve-month Outcomes of the TaurusOne Valve for Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis

Clinical efficacy of transcatheter aortic valve replacement in treatment of patients with aortic valve stenosis based in a single Chinese center

Transcatheter aortic valve replacement in 2016

Transcatheter aortic valve replacement in China - a review of the available evidence

Evaluation of the Safety and Efficacy of Transcatheter Aortic Valve Implantation in Patients with a Severe Stenotic Bicuspid Aortic Valve in a Chinese Population.

Transcatheter Aortic Valve Replacement for Bicuspid Vs. Tricuspid Aortic Stenosis among Patients at Low Surgical Risk in China: from the Multicenter National NTCVR Database

Characteristics and outcomes following transcatheter aortic valve replacement in China: a report from China aortic valve transcatheter replacement registry (CARRY)

Interpretation of 2015 Experts Consensus for Transcatheter Aortic Valve Replacement

Clinical study of anesthesia management and treatment strategies for emergency transcatheter aortic valve replacement

Morphological Characteristics of Severe Aortic Stenosis in China: Imaging Corelab Observations from the First Chinese Transcatheter Aortic Valve Trial

Expansion of indications for transcatheter aortic valve replacement

Update of Transcatheter Valve Treatment

Temporal trends of transcatheter aortic valve replacement outcomes in a high-volume center from China

[Chinese guideline for the clincal application of transcatheter aortic valve replacement]

Heart team construction and operation in transcatheter aortic valve replacement

First-in-man implantation of the retrievable and repositionable VenusA-Plus valve.

An Updated Comprehensive Review of Existing Transcatheter Aortic Valve Replacement Access